Patel S R, Burgess M A, Plager C, Papadopoulos N E, Linke K A, Benjamin R S
Department of Melanoma/Sarcoma Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Cancer. 1994 Aug 15;74(4):1265-9. doi: 10.1002/1097-0142(19940815)74:4<1265::aid-cncr2820740414>3.0.co;2-x.
Myxoid liposarcoma (ML) is the most common type of liposarcoma. It has been classified as an intermediate grade tumor with a definite metastatic potential but a relatively indolent natural history. Little is known about its sensitivity to chemotherapy.
The authors reviewed their experience with chemotherapy in ML from 1986 to 1992. The patient population was identified through a search of the database maintained by the Department of Melanoma-Sarcoma Medical Oncology of the M.D. Anderson Cancer Center.
Forty-four patients each with a histologically confirmed diagnosis of ML were identified. Twenty-one were treated with chemotherapy. The median age was 45 years (31-69 years); there were 14 men and 7 women. The ML in 19 patients was in the lower extremity, one in the head and neck, and one pelvic. The median size of the primary tumor was 15 cm (range, 7-48 cm) in maximum dimension. Of the 18 patients who received doxorubicin- and dacarbazine-based chemotherapy as a frontline regimen [median of 3 (2-9) cycles] and were evaluable for response, 8 (1 completed response, 7 partial responses) achieved an objective response (44%, 95% confidence interval 21-67%). Two of the remaining three patients who were also treated with a similar regimen were not evaluable for response (one received chemotherapy postoperatively, and the other received concomitant radiation and doxorubicin), and the third patient received ifosfamide as frontline chemotherapy because of a significant cardiac history. Seven patients received chemotherapy in the neoadjuvant setting, 13 for recurrent or metastatic disease, and 1 postoperatively after complete tumor resection. At the last follow-up, 10 patients were alive with no evidence of disease, 3 were alive with disease, and 8 had died. The median follow-up was 51 months (range, 6-199 months) from diagnosis.
The authors conclude that doxorubicin- and dacarbazine-based chemotherapy is effective in the treatment of ML.
黏液样脂肪肉瘤（ML）是最常见的脂肪肉瘤类型。它被归类为具有明确转移潜能但自然病程相对惰性的中级肿瘤。关于其对化疗的敏感性知之甚少。
作者回顾了1986年至1992年期间他们在ML化疗方面的经验。通过搜索由MD安德森癌症中心黑色素瘤-肉瘤医学肿瘤学系维护的数据库确定患者群体。
确定了44例经组织学确诊为ML的患者。21例接受了化疗。中位年龄为45岁（31 - 69岁）；男性14例，女性7例。19例患者的ML位于下肢，1例位于头颈部，1例位于盆腔。原发肿瘤的最大径中位大小为15 cm（范围7 - 48 cm）。18例接受以阿霉素和达卡巴嗪为基础的化疗作为一线方案[中位3（2 - 9）周期]且可评估反应的患者中，8例（1例完全缓解，7例部分缓解）达到客观反应（44%，95%置信区间21 - 67%）。其余3例也接受类似方案治疗的患者中，2例不可评估反应（1例术后接受化疗，另1例接受同步放疗和阿霉素），第3例患者因有严重心脏病史接受异环磷酰胺作为一线化疗。7例患者在新辅助治疗中接受化疗，13例用于复发或转移性疾病，1例在肿瘤完全切除术后接受化疗。在最后一次随访时，10例患者无疾病证据存活，3例带瘤存活，8例死亡。从诊断开始的中位随访时间为51个月（范围6 - 199个月）。
作者得出结论，以阿霉素和达卡巴嗪为基础的化疗对ML治疗有效。
